SecSonar.com

Stoke Therapeutics, Inc. (STOK)

Stoke Therapeutics, Inc. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.

Stoke Therapeutics, Inc. (STOK) is a Biotechnology company based in US with a market capitalization of $1.9B. Revenue grew 404.5% year-over-year and the company generated $44.9M in free cash flow. This page tracks STOK's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.

US · 128 employees · IPO Jun 19, 2019

Valuation

Valuation & price

$30.08 · as of May 17, 2026 · -21.6% vs 52w high

—

P/E ratio

Latest-FY diluted EPS

5.47

P/B ratio

Market cap ÷ book equity

—

Dividend yield

Price — last 12 months

$38.35$25.02$11.69Jul 25Dec 25Jul 26Jul 7, 25$11.69Jul 9, 25$12.02Jul 11, 25$11.86Jul 15, 25$11.75Jul 17, 25$12.35Jul 21, 25$12.31Jul 23, 25$14.27Jul 25, 25$13.10Jul 29, 25$12.50Jul 31, 25$12.85Aug 4, 25$13.14Aug 6, 25$13.17Aug 11, 25$13.16Aug 13, 25$16.91Aug 15, 25$18.21Aug 19, 25$18.49Aug 21, 25$19.68Aug 25, 25$18.87Aug 27, 25$19.30Aug 29, 25$19.76Sep 3, 25$19.77Sep 5, 25$20.68Sep 9, 25$22.07Sep 11, 25$23.88Sep 16, 25$23.16Sep 18, 25$23.50Sep 22, 25$22.85Sep 24, 25$22.85Sep 26, 25$24.14Sep 30, 25$23.50Oct 2, 25$24.82Oct 6, 25$26.81Oct 8, 25$30.50Oct 10, 25$30.19Oct 14, 25$34.94Oct 16, 25$34.17Oct 21, 25$34.68Oct 23, 25$31.69Oct 27, 25$33.00Oct 29, 25$31.41Oct 31, 25$30.04Nov 4, 25$25.34Nov 6, 25$22.47Nov 10, 25$22.37Nov 12, 25$25.13Nov 14, 25$26.51Nov 18, 25$28.92Nov 20, 25$27.93Nov 25, 25$29.82Nov 28, 25$30.91Dec 2, 25$29.81Dec 4, 25$31.05Dec 8, 25$33.00Dec 10, 25$34.15Dec 12, 25$32.39Dec 16, 25$33.61Dec 18, 25$31.93Dec 22, 25$33.52Dec 24, 25$32.17Dec 29, 25$32.18Jan 2, 26$30.90Jan 6, 26$35.22Jan 8, 26$33.68Jan 12, 26$29.42Jan 14, 26$30.97Jan 16, 26$28.70Jan 21, 26$29.50Jan 23, 26$29.46Jan 27, 26$29.51Jan 29, 26$31.07Feb 2, 26$30.77Feb 4, 26$32.00Feb 9, 26$31.99Feb 11, 26$32.22Feb 13, 26$31.91Feb 18, 26$30.98Feb 20, 26$34.29Feb 24, 26$35.50Feb 26, 26$35.55Mar 2, 26$36.69Mar 4, 26$34.42Mar 6, 26$35.48Mar 10, 26$38.35Mar 12, 26$36.48Mar 17, 26$32.87Mar 19, 26$33.19Mar 23, 26$33.40Mar 25, 26$33.79Mar 27, 26$32.85Mar 31, 26$32.56Apr 2, 26$32.74Apr 7, 26$33.78Apr 9, 26$35.15Apr 13, 26$35.05Apr 15, 26$35.54Apr 17, 26$37.27Apr 22, 26$35.90Apr 24, 26$34.03Apr 28, 26$33.33Apr 30, 26$32.72May 4, 26$34.18May 6, 26$33.28May 8, 26$32.89May 12, 26$32.49May 14, 26$31.36May 18, 26$29.03May 20, 26$30.30May 22, 26$29.34May 28, 26$31.61Jun 1, 26$30.47Jun 3, 26$29.46Jun 5, 26$30.01Jun 9, 26$29.37Jun 11, 26$29.36Jun 15, 26$30.00Jun 17, 26$30.26Jun 22, 26$30.97Jun 24, 26$30.39Jun 26, 26$32.00Jul 2, 26$32.70
$11.6952-week range$38.35
Loading valuation history…

Fundamentals

Key fundamentals

$1.9B

Market cap

404.5%

Revenue growth (YoY)

100.0%

Gross margin

$44.9M

Free cash flow (USD)

-$284.7M

Net debt

Net cash position

9.7%

Share dilution

1/5

Graham criteria passed

Defensive-investor screen

Healthcare

Sector

Trajectory

Long-term trends

Revenue by year

2017 → 2025

FY 2017$0.00FY 2018$0.00FY 2019$0.00FY 2020$0.00FY 2021$0.00FY 2022$12.4MFY 2023$8.8MFY 2024$36.6MFY 2025$184.4M
$0$184.4M

Free cash flow by year

2017 → 2025

FY 2017$-5.5MFY 2018$-11.9MFY 2019$-32.7MFY 2020$-43.3MFY 2021$-68.1MFY 2022$-35.8MFY 2023$-82.7MFY 2024$-87.1MFY 2025$44.9M
-$5.5M$44.9M

Gross margin by year

2022 → 2025

FY 2022100.0%FY 2023100.0%FY 2024100.0%FY 2025100.0%
100.0%100.0%

Value screen

Graham defensive-investor tests

Computing the scorecard — refreshing any stale inputs…

0

Insider buys · 90 days

3

Insider sells · 90 days

Earnings

Last report: 10-Q filed May 7, 2026

Next expected: not yet scheduled

On the tape

Recent SEC & insider activity

  • 8-K eventEnrollment CompletionJun 30, 2026Filing
  • Insider sellInsider Sell $44K · 10b5-1 PlanAllan Jonathan · GENERAL COUNSEL & CORP SEC · $43.6KJun 18, 2026Filing
  • 8-K eventAnnual Meeting ResultsJun 4, 2026Filing
  • Insider sellInsider Sell $55K · 10b5-1 PlanTicho Barry · CHIEF MEDICAL OFFICER · $54.9KJun 3, 2026Filing
  • Quarterly report10-Q FiledMay 7, 2026Filing
  • 8-K eventEarnings ReleaseMay 7, 2026Filing
  • Insider sellInsider Sell $74K · 10b5-1 PlanTicho Barry · CHIEF MEDICAL OFFICER · $73.5KMay 5, 2026Filing
  • 8-K eventDirector AppointmentApr 7, 2026Filing
  • Insider sellInsider Sell $60K · 10b5-1 PlanTicho Barry · CHIEF MEDICAL OFFICER · $60KApr 3, 2026Filing

Questions

Frequently asked questions

What is Stoke Therapeutics, Inc.'s market cap?

Stoke Therapeutics, Inc. (STOK) has a market capitalization of $1.9B.

What is STOK's P/E ratio?

A meaningful P/E ratio is not available for STOK — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.

What is STOK's price-to-book (P/B) ratio?

STOK trades at 5.47 times book value per share.

Are insiders buying STOK stock?

SEC Form 4 filings show no open-market insider buys at Stoke Therapeutics, Inc. in the last 90 days (3 sells).

Same arena

Related companies in Biotechnology

AUPH

Aurinia Pharmaceuticals Inc.

$2B

SRPT

Sarepta Therapeutics, Inc.

$1.9B

ADMA

ADMA Biologics, Inc.

$1.9B

ABCL

AbCellera Biologics Inc.

$1.9B

GLPG

Galapagos N.V.

$1.9B

MESO

Mesoblast Limited

$2B

Timeline

Every filing, insider trade & earnings on a price-anchored timeline

Filing Analyzer

Search the actual 10-K / 10-Q text with AI research angles

News

Latest press coverage in one feed

Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.